EuPRAXIA preparatory phase project

Fonte Standard Gras
Identifiant

Unité de recherche

SEFRI

Numéro de projet

22.00206

Titre du projet

EuPRAXIA preparatory phase project

Textes relatifs à ce projet

	Allemand	Français	Italien	Anglais
Résumé des résultats (Abstract)	-	-	-

Textes saisis

Catégorie	Texte
Résumé des résultats (Abstract) (Anglais)	EuPRAXIA is a distributed, compact and innovative accelerator facility based on plasma technology. It has been selected for the 2021 Update of the ESFRI Roadmap. In its first phase, its consortium of 51 institutes and industry partners will construct an electron-beam-driven plasma accelerator in the metropolitan area of Rome, thus bringing innovation, potential for spin-off companies, state-of-the art scientific applications and a vibrant international user community to the middle of Italy. In its second phase, EuPRAXIA will build one laser-driven plasma accelerator at a site to be chosen between several options in Europe. EuPRAXIA will serve users in ultra-fast science, e.g. on high-resolution medical imaging, deeply penetrating positron annihilation spectroscopy for materials and with Europe’s most southern free-electron laser (FEL). It will offer fascinating capabilities for research on biomolecules, viruses and microscopic processes. EuPRAXIA will thus be a transformative step in the development of ultra-compact accelerators and applications. The Preparatory Phase project EuPRAXIA-PP will prepare its full implementation.

Catégorie

Texte

Résumé des résultats (Abstract)
(Anglais)

EuPRAXIA is a distributed, compact and innovative accelerator facility based on plasma technology. It has been selected for the 2021 Update of the ESFRI Roadmap. In its first phase, its consortium of 51 institutes and industry partners will construct an electron-beam-driven plasma accelerator in the metropolitan area of Rome, thus bringing innovation, potential for spin-off companies, state-of-the art scientific applications and a vibrant international user community to the middle of Italy. In its second phase, EuPRAXIA will build one laser-driven plasma accelerator at a site to be chosen between several options in Europe. EuPRAXIA will serve users in ultra-fast science, e.g. on high-resolution medical imaging, deeply penetrating positron annihilation spectroscopy for materials and with Europe’s most southern free-electron laser (FEL). It will offer fascinating capabilities for research on biomolecules, viruses and microscopic processes. EuPRAXIA will thus be a transformative step in the development of ultra-compact accelerators and applications. The Preparatory Phase project EuPRAXIA-PP will prepare its full implementation.